Dishman Carbogen Amcis Clarifies Credit Rating Downgrade by India Ratings
Dishman Carbogen Amcis Limited clarifies its credit rating downgrade by India Ratings to 'A' and 'A1' with a negative outlook. The company noted an improvement in net leverage to 3.18x as of September 30, 2025, from 3.92x on March 31, 2025. EBITDA margins are also improving, excluding new French and Indian sites.
A credit rating downgrade can impact borrowing costs and investor confidence. While the company provides mitigating factors, the downgrade itself is material.
The sentiment is neutral as the company is clarifying a rating downgrade, which is a negative event. However, the clarification highlights positive operational improvements like reduced leverage and improving EBITDA margins, which somewhat mitigates the negative impact.
Dishman Carbogen Amcis Limited (DCAL) has issued a clarification regarding the recent downgrade of its long-term and short-term credit ratings by India Ratings & Research Pvt. Ltd. (IND-RA). The company's India credit facilities were downgraded to 'A' and 'A1' respectively, with a negative outlook.
DCAL acknowledges that the rating downgrade was based on a consolidated view. However, the company asserts that this action does not reflect the improving business and financial performance of the Group. The last rating exercise by India Ratings in April 2025 had affirmed the ratings at 'A+' and 'A1+' with a stable outlook.
The company highlighted that its net leverage as of 30th September, 2025, had improved to 3.18x compared to 3.92x as of 31st March, 2025. This improvement is further accentuated when excluding notional foreign exchange impacts, where the leverage was 3.07x and 3.85x, respectively. Furthermore, the consolidated EBITDA margins for the Group have shown improvement, particularly when excluding the newer French site and the recently re-approved India site, when compared to pre-EDQM observation period margins.
DCAL expects to achieve EBITDA margins at the pre-EDQM observation level of 24.4% with the scaling up of business at the new French facility and the re-approved Bavla site in India, alongside continued growth at other sites. The EBITDA margins generated in FY25 and the nine months ended December 31, 2025, excluding those from France and India sites, demonstrate this growth.
What to do with a filing like this
Dishman Carbogen Amcis Limited filed this with the NSE as a statutory disclosure, categorised under other regulatory filings. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Dishman Carbogen Amcis Limited. Read the original for the full detail.